Repeated DermaVir Immunizations in HIV-1 Infected Treatment-naïve Patients

Overview

DermaVir is a synthetic pathogen-like nanomedicine. The active pharmaceutical ingredient is a single plasmid DNA expressing fifteen HIV antigens that assemble to HIV-like particles. These particles are safe; replication, integration and reverse transcription deficient. DermaVir is targeted to Langerhans cells by topical administration with DermaPrep. Langerhans cells with DermaVir migrate to lymph nodes and induce HIV-specific T cells that can kill HIV-infected cells. GIEU006 is a Phase II randomized, placebo-controlled, dose-finding, double-blinded, multicenter study to assess the safety, tolerability, immunogenicity, and preliminary antiretroviral activity of DermaVir in antiretroviral therapy naïve adults with HIV-infection.

Patients were randomized into one of the following 6 arms: * Arm 1: Low dose DermaVir (0.2 mg DNA in 2 DermaPrep patches, n=9) * Arm 2: Low dose Placebo (2 DermaPrep patches, n=3) * Arm 3: Medium dose DermaVir (0.4 mg DNA in 4 DermaPrep patches, n=9) * Arm 4: Medium dose Placebo (4 DermaPrep patches, n=3) * Arm 5: High dose DermaVir (0.8 mg DNA in 8 DermaPrep patches, n=9) * Arm 6: High dose Placebo (8 DermaPrep patches, n=3) DermaPrep Patch size: 80 cm2. DermaVir Standard Unit per patch is 0.1 mg DNA = 0.8 mL of DermaVir nanomedicine. The patch sites for immunization are preferably the left or right upper back and left or right upper ventral thigh. The same skin sites should be used for all immunizations. Immunization schedule (Days): 0, 42, 84, and 126. The total DermaVir dose: * Low dose: 0.8 mg DNA * Medium dose: 1.6 mg DNA * High Dose: 3.2 mg DNA DermaVir immunizations were administered over an 18-week period Primary endpoint: 24 weeks Safety follow up: 234 weeks